Analysts eye Pfizer break-up
Analysts have been eyeing the prospect of a Pfizer break-up; they figure Pfizer would be worth $180 billion in pieces, according to Fierce Pharma.
Fierce notes some of Forbes quotes for potential prices of Pfizer units--animal health, $16 billion; nutritionals, $8 billion; and consumer health, $6 billion; established products business, which sells off-patent drugs, $40 billion. The rest of core business would be estimated at $110 billion.
The divestment is creating lots of buzz, even though the strategic review of Pfizer assets will likely continue for the rest of this year. CEO Ian Read seems to be leaning toward some sell-offs, reports Fierce Pharma. "My sense is he's already made up his mind," says Goldman Sachs analyst Jami Rubin, who's been calling for a Pfizer break-up for years.